Stockscreener 앱 받기
2.33
3.32%
-0.08
시간 외 거래:
2.32
-0.01
-0.43%
전일 마감가:
$2.41
열려 있는:
$2.4
하루 거래량:
41,644
Relative Volume:
0.45
시가총액:
$10.58M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-3.1067
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
+1.75%
1개월 성능:
+15.75%
6개월 성능:
-49.14%
1년 성능:
-66.23%
1일 변동 폭
$2.30
$2.5107
1주일 범위
$2.29
$2.65
52주 변동 폭
$1.91
$16.70
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.33 | 10.94M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.86 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.95 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
804.90 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.80 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Layoff Tracker: Novo’s Cuts Leave Dozens of Manufacturing Workers Jobless - BioSpace
Bio, semiconductor, content firms to reboot Korea’s IPO market - The Korea Economic Daily Global Edition
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Nuvation Bio: A Rare Gem In The Risky Biotech Space (NYSE:NUVB) - Seeking Alpha
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes - biospace.com
KALA BIO Soars 10.65% on Bullish Analyst Coverage - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Does Gossamer Bio Inc. align with a passive investing strategyJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.60%
자본화:
|
볼륨(24시간):